July 22, 2025 • FierceBiotech Replimune's shares crater as FDA rejects melanoma drug - Fierce Biotech The FDA has Share this article Twitter Facebook LinkedIn WhatsApp Telegram Email Reddit More from our blog FDA names 9 first recipients of 1- to 2-month priority review vouchers - Fierce Biotech 8 months ago CSL to lay off up to 15% of workforce, cut R&D costs and spin out vaccine unit - Fierce Biotech 10 months ago Back to Blog
CSL to lay off up to 15% of workforce, cut R&D costs and spin out vaccine unit - Fierce Biotech 10 months ago
